A PHASE I STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF HIGH DOSES OF CAMOSTAT MESYLATE IN HEALTHY SUBJECTS PROVIDES A RATIONALE TO REPURPOSE THE TMPRSS2 INHIBITOR FOR THE TREATMENT OF COVID-19.

被引：0
|
作者：
Kitagawa, J. [1 ]
Arai, H. [1 ]
Iida, H. [1 ]
Mukai, J. [1 ]
Furukawa, K. [1 ]
Ohtsu, S. [1 ]
Nakade, S. [1 ]
Hikima, T. [2 ]
Haranaka, M. [3 ]
Uemura, N. [4 ]
机构：
[1] Ono Pharmaceut, Osaka, Japan
[2] Kyushu Inst Technol, Fukuoka, Japan
[3] SOUSEIKAI Hakata Clin, Fukuoka, Japan
[4] Oita Univ, Oita, Japan
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2021年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-052
引用
收藏
页码：S43 / S43
页数：1
相关论文
共 50 条
  • [1] A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19
    Kitagawa, Junsaku
    Arai, Hayato
    Iida, Hiroyuki
    Mukai, Jiro
    Furukawa, Kenji
    Ohtsu, Seitaro
    Nakade, Susumu
    Hikima, Tomohiro
    Haranaka, Miwa
    Uemura, Naoto
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (05): : 1967 - 1976
  • [2] PBPK MODEL FOR CAMOSTAT, A REPURPOSED TMPRSS2 INHIBITOR, PREDICTS THE OPTIMAL DOSE FOR THE TREATMENT OF COVID-19.
    Wakuda, H.
    Nitawaki, M.
    Uemoto, Y.
    Sekiguchi, A.
    Kuranari, M.
    Otani, N.
    Katoh, A.
    Hojo, T.
    Imai, H.
    Uemura, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S44 - S44
  • [3] A phase I, randomized study to evaluate the safety, tolerability, and pharmacokinetics of mefunidone in healthy subjects
    Han, Mai
    Huo, Bishan
    Hu, Gaoyun
    Zhang, Xin
    Cui, Gang
    Wu, Wei
    Mi, Na
    Zhang, Shixi
    Jin, Jiangli
    Lu, Xing
    Wu, Bidong
    Xiao, Chunyan
    Wang, Jing
    Bian, Zheng
    Li, Jintong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [4] Phase I study in healthy participants to evaluate safety, tolerability, and pharmacokinetics of inhaled nezulcitinib, a potential treatment for COVID-19
    Pfeifer, Nathan D.
    Lo, Arthur
    Bourdet, David L.
    Colley, Kenneth
    Singh, Dave
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2021, 14 (06): : 2556 - 2565
  • [5] A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects
    Qian, Hongjie
    Chen, Qian
    Lang, Liyu
    Zou, Yang
    Pu, Huahua
    Xin, Liang
    Song, Rong
    Li, Tingting
    Zhu, Huijuan
    Wang, Yu
    Tian, Guanghui
    Shen, Jingshan
    Jiang, Hualiang
    Yu, Chen
    Wang, Zhen
    Jia, Jingying
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 2947 - 2959
  • [6] Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
    G Tong
    I Savant
    N Jariwala
    D Burt
    N Zheng
    A Buzescu
    R Bertz
    S Keswani
    R Marcus
    The Journal of Headache and Pain, 2013, 14
  • [7] Phase I single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of BMS-927711 in healthy subjects
    Tong, G.
    Savant, I.
    Jariwala, N.
    Burt, D.
    Zheng, N.
    Buzescu, A.
    Bertz, R.
    Keswani, S.
    Marcus, R.
    JOURNAL OF HEADACHE AND PAIN, 2013, 14
  • [8] A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BGT-002, a Novel ATP-Citrate Lyase Inhibitor, in Healthy Chinese Subjects
    Liu, Yun
    Yu, Chengyin
    Zhang, Yifan
    Xie, Zhifu
    Wang, Yating
    Qian, Hongjie
    Liang, Liyu
    Liu, Yanmei
    Chen, Qian
    Jia, Jingying
    Yan, Sai
    Lai, Xiaoyin
    Li, Wei
    Li, Jingya
    Zhang, Yangming
    Nan, Fajun
    Yu, Chen
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 : 1783 - 1794
  • [9] A phase I, first-in-human study to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of MRG-001 in healthy subjects
    Ahmadi, Ali R.
    Atiee, George
    Chapman, Bart
    Reynolds, Laurie
    Sun, John
    Cameron, Andrew M.
    Wesson, Russell N.
    Burdick, James F.
    Sun, Zhaoli
    CELL REPORTS MEDICINE, 2023, 4 (09)
  • [10] A phase I study to evaluate the safety, tolerability, and pharmacokinetics of a novel, potent GABA analog HSK16149 in healthy Chinese subjects
    Chen, Qian
    Wu, Qingqing
    Song, Rong
    Wang, Yating
    Zhang, Mengqi
    Li, Fangqiong
    Zeng, Weifang
    Wang, Wei
    Jia, Jingying
    Yu, Chen
    Liu, Yanmei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
12345